Drugs / Gabapentin
Gabapentin
also known as
Neurontin · Gralise · G-ER · gabapentine · GBP · Neurontin (Registered Trademark) · Conventin · G-GR · +8 more
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | NEURONTIN | — | 1998-09-29 – 2002-08-15 | fda.gov ↗ |
| Approved | US (FDA) | NEURONTIN | — | 1993-12-30 | fda.gov ↗ |
Trials 244 · started per year
today
US approved 1993
1
1
2
2
1
5
5
5
13
10
10
9
7
8
10
3
6
8
11
14
8
20
15
16
10
11
11
6
5
4
6
1
1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 08 trials | ||||||
| Phase 0 | NCT05533684 | Sep → Dec 2022 | neuropathy, painful | Minia University | Completed | No outcome recorded |
| Phase 0 | NCT04631510 | Dec 2020 → Aug 2023 | — | Tufts Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT04620720 | Aug → Dec 2020 | — | Combined Military Hospital, Pakistan | Unknown | No outcome recorded |
| Phase 0 | NCT03820193 | Jan 2019 → Jun 2020 | substance-related disorder | Henry Ford Health System | Completed | No outcome recorded |
| Phase 0 | NCT03589898 | Sep 2017 → Aug 2022 | autism spectrum disorder | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 0 | NCT02856750 | Oct 2016 → Oct 2018 | — | Denver Health and Hospital Authority | Completed | No outcome recorded |
| Phase 0 | NCT03346668 | Jan 2016 → Oct 2021 | central centrifugal cicatricial alopecia, frontal fibrosing alopecia, lichen planopilaris | University of Minnesota | Completed | No outcome recorded |
| Phase 0 | NCT01441531 | Jan 2012 → Jun 2014 | — | Baylor College of Medicine | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 115 trials | ||||||
| Phase 1 | NCT04658732 | Dec 2020 → Jun 2021 | — | Ehab Tarek Fahmy | Unknown | No outcome recorded |
| Phase 1 | NCT04315181 | Mar 2019 → May 2023 | substance-related disorder | Sharon Walsh | Completed | No outcome recorded |
| Phase 1 | NCT02531906 | Apr 2015 → Jun 2018 | head and neck squamous cell carcinoma, stomatitis | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02056899 | Jun 2013 → Aug 2015 | — | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 1 | NCT01485185 | Oct 2011 → Jul 2012 | neuropathy, painful | GlaxoSmithKline | Completed | Mixed |
| Phase 1 | NCT01421264 | Aug 2011 → Dec 2012 | insomnia | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 1 | NCT01092520 | Jul 2009 → Jul 2011 | — | The Hospital for Sick Children | Withdrawn | No outcome recorded |
| Phase 1 | NCT00733239 | Aug 2008 → Oct 2010 | opiate dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT00593463 | Sep 2006 → May 2010 | drug dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT00865423 | Feb 2001 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00865059 | Feb 2001 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00865631 | Jun 1999 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00864760 | Jun 1999 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00864058 | Jan 1998 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00864305 | Dec 1997 → Jan 1998 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07846020 | Jan 2027 → Jan 2032 expected | chronic pain syndrome | University of Maryland, Baltimore | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06705101 | Dec 2024 → Jun 2025 overdue | — | Liaquat National Hospital & Medical College | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05664464 | Jan 2023 → Jun 2026 overdue | glioblastoma | University of Zurich | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05156060 | Jan 2022 → Dec 2025 overdue | head and neck carcinoma | Natalie Lockney | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02557945 | Aug 2015 → Jun 2016 | early-onset schizophrenia | New York State Psychiatric Institute | Terminated | No outcome recorded Stop: Business |
| Phase 235 trials · 5 met primary · 5 missed | ||||||
| Phase 2 | NCT05064319 | Feb 2022 → Jul 2026 | bipolar I disorder, bipolar II disorder, cannabis dependence, schizoaffective bipolar disorder | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT05184192 | Jan 2022 → Aug 2023 | COVID-19, anosmia, olfactory nerve disorder | Washington University School of Medicine | Completed | Missed primary |
| Phase 2 | NCT04766229 | Jun 2021 → Nov 2022 | cancer, insomnia | University College Dublin | Completed | No outcome recorded |
| Phase 2 | NCT04619862 | May 2021 → Mar 2026 | neuropathy, painful | University of British Columbia | Unknown | No outcome recorded |
| Phase 2 | NCT04429347 | Jul 2020 → Dec 2024 | chronic pain syndrome, insomnia | University of California, San Diego | Completed | No outcome recorded |
| Phase 2 | NCT03679013 | Apr → Jul 2019 | — | Inova Health Care Services | Completed | No outcome recorded |
| Phase 2 | NCT03708237 | Feb → Nov 2019 | end stage renal failure, restless legs syndrome | University of Alberta | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03818919 | Jan 2019 → Dec 2020 | rotator cuff syndrome | Henry Ford Health System | Completed | No outcome recorded |
| Phase 2 | NCT03749642 | Nov 2018 → Jun 2020 | diabetic polyneuropathy | Angelini Pharma | Completed | Missed primary |
| Phase 2 | NCT03423264 | Jan 2018 → Nov 2022 | human papillomavirus-related squamous cell carcinoma, oropharynx cancer | University of Chicago | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03334721 | Oct 2017 → Jul 2019 | bipolar I disorder, bipolar II disorder, cannabis dependence | Medical University of South Carolina | Completed | Missed primary |
| Phase 2 | NCT03220776 | Aug 2017 → Nov 2022 | alcohol-related disorders, bipolar disorder | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT03275012 | Apr 2017 → Oct 2019 | chronic pain syndrome | Pharmaceutical Research Management srl | Withdrawn | No outcome recorded |
| Phase 2 | NCT02349477 | Nov 2014 → Aug 2018 | alcohol dependence, alcohol withdrawal | Medical University of South Carolina | Completed | Met primary |
| Phase 2 | NCT02163434 | Jun 2014 → Oct 2019 | hyperemesis gravidarum | State University of New York at Buffalo | Completed | Met primary |
| Phase 2 | NCT03023501 | Mar 2014 → Jan 2017 | — | King Saud University | Completed | No outcome recorded |
| Phase 2 | NCT01893632 | Jul 2013 → Apr 2016 | drug dependence | New York State Psychiatric Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01744444 | Nov 2012 → Jul 2013 | pathologic nystagmus | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 2 | NCT01675960 | Apr 2012 → Jul 2017 | chronic pain syndrome, digestive system disorder, insomnia, mood disorder +1 | Gillette Children's Specialty Healthcare | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01533753 | Feb 2012 → Jan 2014 | prostate cancer | University of Wisconsin, Madison | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00974376 | Nov 2009 → May 2016 | cannabis dependence, cognitive disorder, substance withdrawal syndrome | The Scripps Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01014520 | May 2009 → Feb 2010 | vertebral column disorder | Tabriz University | Unknown | No outcome recorded |
| Phase 2 | NCT01005108 | Jan 2009 → Jan 2014 | — | Abramson Cancer Center at Penn Medicine | Completed | Met primary |
| Phase 2 | NCT00420771 | Jan 2007 → Jan 2011 | opiate dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT00395044 | Aug 2006 → Jul 2008 | cannabis dependence | The Scripps Research Institute | Completed | Met primary |
| Phase 2 | NCT00712439 | Apr → Nov 2006 | diabetic polyneuropathy | Depomed | Completed | No outcome recorded |
| Phase 2 | NCT00654953 | Jan 2006 → May 2009 | cocaine dependence, depressive disorder | University of Arkansas | Completed | Missed primary |
| Phase 2 | NCT00755508 | Nov 2005 → Sep 2006 | sleep disorder, initiating and maintaining sleep | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT00108550 | Oct 2004 → Jul 2009 | chronic pain syndrome | US Department of Veterans Affairs | Completed | Missed primary |
| Phase 2 | NCT00391716 | Feb 2004 → Jul 2009 | alcohol dependence | The Scripps Research Institute | Completed | Met primary |
| Phase 2 | NCT00257270 | Aug 2003 → Jan 2005 | tinnitus | Tinnitus Research Consortium | Completed | No outcome recorded |
| Phase 2 | NCT01210079 | Sep 2002 → Mar 2008 | — | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT00229125 | Jul 2001 → Sep 2005 | alcohol withdrawal | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2 | NCT00001482 | May 1995 → May 2001 | anxiety disorder, mood disorder, psychotic disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2 | NCT00011297 | ? → Dec 2005 | alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2/311 trials · 1 met primary · 2 missed | ||||||
| Phase 2/3 | NCT04939987 | Aug → Oct 2022 | — | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03825809 | Jan 2019 → Jan 2020 overdue | substance-related disorder | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03818932 | Jan 2019 → Jan 2020 | — | Henry Ford Health System | Completed | Mixed |
| Phase 2/3 | NCT03566394 | Jul 2018 → Jun 2019 | chemotherapy-induced toxicity, invasive breast carcinoma | British Columbia Cancer Agency | Unknown | No outcome recorded |
| Phase 2/3 | NCT03496389 | Jul 2018 → Jul 2019 | — | Hospital Authority, Hong Kong | Unknown | No outcome recorded |
| Phase 2/3 | NCT02355886 | Apr 2015 → Feb 2018 | urinary bladder carcinoma | University of Washington | Completed | No outcome recorded |
| Phase 2/3 | NCT02099006 | Nov 2013 → Jun 2015 | female reproductive system disorder | University of Rochester | Completed | Missed primary |
| Phase 2/3 | NCT01486706 | Oct 2010 → Oct 2014 | overactive bladder | Michael E. Chua | Completed | No outcome recorded |
| Phase 2/3 | NCT00262639 | Dec 2005 → Feb 2008 | alcohol dependence | Medical University of South Carolina | Completed | Met primary |
| Phase 2/3 | NCT00317850 | Apr 2004 → Feb 2006 | tinnitus | Washington University School of Medicine | Terminated | Missed primary |
| Phase 2/3 | NCT00057278 | Mar 2003 → Jan 2006 | fibromyalgia | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | No outcome recorded |
| Phase 356 trials · 7 met primary · 9 missed | ||||||
| Phase 3 | NCT02219373 | Jun 2026 → Dec 2028 | neuropathy, painful | Boston Children's Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT07429734 | Feb → Oct 2026 expected | overactive bladder | Mansoura University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06992427 | Jun 2025 → Aug 2029 expected | head and neck squamous cell carcinoma | Alliance for Clinical Trials in Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT05921604 | Jun 2023 → Aug 2025 overdue | — | Tanta University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05620641 | Oct 2022 → Feb 2025 | morbid obesity | Tanta University | Completed | No outcome recorded |
| Phase 3 | NCT05100160 | Sep 2021 → Jan 2023 | lung disorder | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04429022 | Nov 2020 → May 2022 | — | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT04230980 | Jul 2020 → Nov 2022 | azoospermia | Weill Medical College of Cornell University | Completed | Met primary |
| Phase 3 | NCT04176419 | Jan 2020 → Jun 2021 | — | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT03867240 | Jun 2019 → Sep 2022 | idiopathic scoliosis, neuropathy, painful | Emory University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03747562 | Mar 2019 → Jul 2022 | head and neck cancer, neuropathy, painful, radiation-induced neuropathy | University Hospital, Ghent | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03682367 | Dec 2018 → Apr 2020 | head and neck cancer | University of California, Davis | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02722603 | Sep 2018 → May 2019 | chronic pain syndrome | Pharmaceutical Research Management srl | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02987985 | Oct 2017 → Sep 2019 | obstructive sleep apnea syndrome, respiratory underresponsiveness to hypoxia and hypercapnia | University of Saskatchewan | Completed | No outcome recorded |
| Phase 3 | NCT03330119 | Oct 2017 → Jun 2018 | pregnancy disorder, substance-related disorder | Brest, Norman A., M.D. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT03186443 | Oct 2017 | neuralgia | Second Affiliated Hospital of Guangzhou Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT03255330 | Oct 2017 → Feb 2020 | spinal cord injury | Masaryk University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03269344 | Jun 2017 → Dec 2020 | oropharynx cancer | Henry Ford Health System | Completed | Missed primary |
| Phase 3 | NCT02999724 | Jan → Sep 2017 | pelvic organ prolapse | Mount Sinai Hospital, Canada | Unknown | Missed primary |
| Phase 3 | NCT02918760 | Mar → Dec 2016 | pelvis syndrome | Ain Shams University | Unknown | Met primary |
| Phase 3 | NCT03158376 | Sep 2015 → May 2019 | chronic pain syndrome | University Hospital, Lille | Completed | No outcome recorded |
| Phase 3 | NCT02480114 | Jul 2015 → Sep 2019 | head and neck cancer, mucositis, radiation-induced disorder | Vanderbilt-Ingram Cancer Center | Completed | Met primary |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT02384187 | Jan → May 2015 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT01888497 | Jul → Dec 2013 | — | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT01776671 | Feb 2013 → Nov 2018 | — | Chicago Anesthesia Pain Specialists | Unknown | No outcome recorded |
| Phase 3 | NCT03274167 | Jan 2012 → Dec 2014 | alcohol abuse | Chulalongkorn University | Completed | No outcome recorded |
| Phase 3 | NCT01080300 | Aug 2010 → Sep 2011 | — | Depomed | Completed | No outcome recorded |
| Phase 3 | NCT01067144 | May 2010 → Jul 2016 | breast cancer, lung cancer | Stanford University | Terminated | Missed primary |
| Phase 3 | NCT01052896 | Mar 2010 → Mar 2011 | dyspepsia | 59th Medical Wing | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01632215 | Mar 2010 → Aug 2011 | carpal tunnel syndrome | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 3 | NCT00880191 | Apr 2009 → Mar 2011 | cancer of unknown primary site | Alliance for Clinical Trials in Oncology | Completed | Missed primary |
| Phase 3 | NCT01052844 | Jan 2009 → Jul 2010 | cisplatin toxicity | Faculdade de Medicina do ABC | Completed | Mixed |
| Phase 3 | NCT00777023 | Oct 2008 → Jul 2009 | — | Depomed | Completed | Mixed |
| Phase 3 | NCT00755417 | Sep 2008 → Aug 2009 | — | Depomed | Completed | Mixed |
| Phase 3 | NCT00684112 | May 2008 → Dec 2009 | scoliosis | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 3 | NCT00620555 | May 2008 → Dec 2010 | focal epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00636636 | Mar 2008 → Aug 2009 | postherpetic neuralgia | Depomed | Completed | Met primary |
| Phase 3 | NCT00603473 | Jan 2008 → Dec 2009 | epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00659100 | Aug 2006 → Jan 2007 | insomnia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00335933 | May 2006 → Jul 2007 | postherpetic neuralgia | Depomed | Completed | Missed primary |
| Phase 3 | NCT00312260 | Apr 2006 → May 2010 | — | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 3 | NCT00674752 | Mar → Aug 2006 | insomnia | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00221338 | Jan 2006 → Jan 2014 | delirium | University of California, San Francisco | Completed | Met primary |
| Phase 3 | NCT00163046 | Oct 2005 → Apr 2006 | insomnia | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00666575 | Dec 2004 → May 2005 | insomnia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00087399 | Nov 2004 → Apr 2007 | breast cancer | Alliance for Clinical Trials in Oncology | Completed | Missed primary |
| Phase 3 | NCT00667108 | Oct 2004 → Jan 2005 | insomnia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00666770 | Oct → Nov 2004 | insomnia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00666939 | Oct 2004 → Jan 2005 | insomnia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01107574 | Apr 2004 → Dec 2009 | fibromyalgia | Good Samaritan Regional Medical Center, Oregon | Completed | No outcome recorded |
| Phase 3 | NCT00533455 | Mar 2004 → Aug 2007 | tremor, hereditary essential, and idiopathic normal pressure hydrocephalus | Minneapolis Veterans Affairs Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00112138 | Mar 2004 → Feb 2006 | — | North Toronto Primary Care Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00027963 | Feb 2002 → Nov 2007 | poisoning | Alliance for Clinical Trials in Oncology | Completed | Missed primary |
| Phase 3 | NCT00058890 | Nov 2000 → Jan 2004 | cholestasis, cirrhosis of liver | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Missed primary |
| Phase 3 | NCT00007670 | Jan 1998 → Mar 2003 | epilepsy | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 475 trials · 5 met primary · 9 missed | ||||||
| Phase 4 | NCT07795593 | Oct 2026 → May 2031 expected | diabetic kidney disease, diabetic neuropathy | University of Michigan | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07840183 | Sep 2026 → Sep 2027 expected | — | Northwestern University | Recruiting | No outcome recorded |
| Phase 4 | NCT06781489 | Feb → Mar 2025 | carpal tunnel syndrome | Universidad Europea de Madrid | Completed | No outcome recorded |
| Phase 4 | NCT06254183 | Dec 2024 → May 2025 | acute kidney injury, morbid obesity | Tanta University | Completed | No outcome recorded |
| Phase 4 | NCT07750639 | Aug 2024 → Nov 2027 expected | drug dependence, opioid abuse, poisoning | AdventHealth | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06379425 | Mar 2024 → Jan 2027 expected | — | Northwell Health | Recruiting | No outcome recorded |
| Phase 4 | NCT05800847 | Apr 2023 → Apr 2024 | rotator cuff syndrome | Hughston Clinic | Unknown | No outcome recorded |
| Phase 4 | NCT05658887 | Jan 2023 → Dec 2024 | pelvic organ prolapse | Joseph Kowalski | Completed | No outcome recorded |
| Phase 4 | NCT05076110 | Apr 2022 → Oct 2025 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT05302999 | Mar 2022 → Mar 2026 | spinal cord injury | MetroHealth Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT05063656 | Feb 2022 → Dec 2025 | autism spectrum disorder | David Cochran | Completed | No outcome recorded |
| Phase 4 | NCT04865042 | Feb 2022 → Dec 2024 | radiculopathy | Lille Catholic University | Completed | No outcome recorded |
| Phase 4 | NCT04860141 | Jun 2021 → Dec 2026 expected | neuropathy, painful, tooth disorder | Loma Linda University | Recruiting | No outcome recorded |
| Phase 4 | NCT03689114 | May 2021 → Jun 2024 | focal epilepsy | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 4 | NCT05319756 | Apr → Dec 2021 | substance abuse | Viatris Specialty LLC | Completed | No outcome recorded |
| Phase 4 | NCT04705480 | Apr 2021 → Sep 2024 | — | CAMC Health System | Completed | Missed primary |
| Phase 4 | NCT05413902 | Apr 2021 → Jan 2022 | — | University of Puerto Rico | Completed | No outcome recorded |
| Phase 4 | NCT04570436 | Mar 2021 → Nov 2022 | substance abuse | Viatris Specialty LLC | Completed | No outcome recorded |
| Phase 4 | NCT04522206 | Aug 2020 → Jun 2021 | vertebral column disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT02927405 | Mar 2020 | — | State University of New York - Downstate Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04246697 | Nov 2019 → Jun 2021 | head and neck cancer | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04068506 | Sep 2019 → Jan 2020 | — | Dow University of Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02957097 | Sep 2019 → Jun 2021 | cranial nerve neuropathy, neuropathy, painful | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT04256603 | Aug 2019 → Mar 2020 | neuropathy, painful, spinal cord injury | MetroHealth Medical Center | Completed | Missed primary |
| Phase 4 | NCT03859024 | Mar 2019 → Apr 2023 | urethral stricture | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT03738904 | Oct 2018 → Aug 2022 | anus disorder | Cedars-Sinai Medical Center | Completed | Met primary |
| Phase 4 | NCT03472521 | Sep 2018 → Jul 2020 | chronic pain syndrome, puerperal disorder, substance-related disorder | Stanford University | Completed | Missed primary |
| Phase 4 | NCT03549611 | Aug 2018 → Jun 2019 | nephrolithiasis | Kevin J Flynn MD | Withdrawn | No outcome recorded |
| Phase 4 | NCT03334903 | May 2018 → Apr 2019 | chronic pain syndrome, opiate dependence, osteoarthritis, knee | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03335436 | Apr 2018 → Nov 2020 | — | Vanderbilt University Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03151746 | Jan 2018 → Dec 2021 | urethral obstruction | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03121963 | Nov 2017 → Nov 2020 | — | University of Alabama at Birmingham | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02160301 | Nov 2017 → Dec 2019 | — | University of North Carolina, Chapel Hill | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05024825 | Aug 2017 → May 2021 | — | Albany Medical College | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03681574 | Jul 2017 → Jul 2018 | acute stress disorder, neuropathy, painful | Hospital Infantil Albert Sabin | Completed | No outcome recorded |
| Phase 4 | NCT03635905 | May 2017 → May 2019 | — | Medstar Health Research Institute | Completed | Missed primary |
| Phase 4 | NCT03393702 | May 2017 → Dec 2019 | neuropathy, painful | National Institute for Tuberculosis and Lung Diseases, Poland | Completed | No outcome recorded |
| Phase 4 | NCT03012815 | Feb 2017 → Mar 2021 | alcohol withdrawal | Mayo Clinic | Completed | Missed primary |
| Phase 4 | NCT02958566 | Jan → Dec 2017 | colon carcinoma, constipation disorder, diverticulitis of colon, paralytic ileus +1 | University of Illinois College of Medicine at Peoria | Unknown | No outcome recorded |
| Phase 4 | NCT02944656 | Dec 2016 → Jun 2018 | — | Emory University | Completed | Missed primary |
| Phase 4 | NCT03241875 | Dec 2016 → Aug 2017 | gallbladder disorder, neuropathy, painful | Faculty of Medicine, Sousse | Completed | Met primary |
| Phase 4 | NCT02944981 | Aug 2016 → Feb 2017 | — | Khon Kaen University | Completed | Met primary |
| Phase 4 | NCT02771925 | Jun 2016 → Apr 2018 | alcohol dependence | Dayanand Medical College and Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT02867176 | Jan → Jul 2016 | — | Instituto de Oftalmología Fundación Conde de Valenciana | Completed | No outcome recorded |
| Phase 4 | NCT02693821 | Dec 2015 → Jan 2016 | — | Hospital Italiano de Buenos Aires | Completed | No outcome recorded |
| Phase 4 | NCT03047278 | Nov 2015 → May 2018 | diabetic neuropathy, neuropathy, painful, type 2 diabetes mellitus | Natalia Valadares de Moraes | Completed | No outcome recorded |
| Phase 4 | NCT02599701 | Sep → Nov 2015 | — | Associação Fundo de Incentivo à Pesquisa | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02466191 | Jun 2015 → Jan 2016 | pathologic nystagmus | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 4 | NCT02359110 | Jun 2015 → Jan 2017 | — | Milton S. Hershey Medical Center | Completed | Missed primary |
| Phase 4 | NCT02595190 | Mar 2015 → Mar 2020 | pain agnosia | Southwest Hospital, China | Unknown | No outcome recorded |
| Phase 4 | NCT02330094 | Dec 2014 → Sep 2017 | acquired aneurysmal subarachnoid hemorrhage | Mayo Clinic | Completed | Missed primary |
| Phase 4 | NCT02127853 | Jul 2014 → Feb 2016 | — | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03005483 | Jan 2014 → Jan 2015 | musculoskeletal system disorder | Hospital Infantil Albert Sabin | Completed | No outcome recorded |
| Phase 4 | NCT01977937 | Nov 2013 → Apr 2018 | neuropathy, painful | Oregon Health and Science University | Completed | Missed primary |
| Phase 4 | NCT01868425 | Apr 2013 → Dec 2017 | — | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 4 | NCT01764464 | Dec 2012 → Mar 2016 | — | University of Rochester | Completed | No outcome recorded |
| Phase 4 | NCT01364298 | Apr 2011 → Jul 2012 | diabetic polyneuropathy | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT01127100 | May 2010 → Nov 2011 | neuropathy, painful, spinal stenosis | Seoul National University Hospital | Completed | Met primary |
| Phase 4 | NCT01177514 | Apr → Sep 2010 | — | Codet Vision Institute | Completed | No outcome recorded |
| Phase 4 | NCT00785772 | Mar → Apr 2010 | impaired renal function disease | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT02074267 | Mar 2009 → Jun 2011 | peripheral neuropathy | Nang Kuang Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00584779 | Oct → Dec 2007 | — | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00855738 | May 2007 → Jun 2009 | focal epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01022736 | May → Sep 2007 | — | Queen's University | Completed | No outcome recorded |
| Phase 4 | NCT01966172 | Mar 2007 → Aug 2009 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT00209885 | Oct 2005 → ? | cholecystolithiasis | Hvidovre University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00209872 | Oct 2005 → ? | — | Hvidovre University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00236223 | Oct 2005 → Apr 2008 | — | Glostrup University Hospital, Copenhagen | Terminated | No outcome recorded |
| Phase 4 | NCT00666796 | Apr → May 2005 | insomnia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01573052 | Mar 2004 → Aug 2010 | alcohol withdrawal | VA Salt Lake City Health Care System | Completed | No outcome recorded |
| Phase 4 | NCT00153283 | Sep 2003 → Apr 2004 | asthma | Centre of Chinese Medicine, Georgia | Completed | No outcome recorded |
| Phase 4 | NCT00644748 | May 2003 → Aug 2004 | diabetic neuropathy | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00189072 | Apr 2003 → ? | neuropathy, painful | UMC Utrecht | Terminated | No outcome recorded |
| Phase 4 | NCT00276081 | May 2002 → Sep 2004 | — | University of Rochester | Completed | Met primary |
| Phase 4 | NCT00169013 | May 2002 → Jun 2006 | — | Danish Pain Research Center | Completed | No outcome recorded |
| Phase not applicable39 trials · 3 met primary · 4 missed | ||||||
| — | NCT07804784 | Jan → May 2026 | breast cancer | Shaukat Khanum Memorial Cancer Hospital & Research Centre | Completed | No outcome recorded |
| — | NCT07169006 | Jan → Jun 2026 overdue | — | Ain Shams University | Not yet recruiting | No outcome recorded |
| — | NCT07389551 | Jul → Dec 2025 | — | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT07019103 | Mar 2025 → Oct 2026 expected | — | Haroon Muhammad Khalil | Active not recruiting | No outcome recorded |
| — | NCT07515456 | Dec 2024 → Nov 2026 expected | intracranial hypotension | Tanta University | Recruiting | No outcome recorded |
| — | NCT05997355 | Sep 2023 → Jul 2024 | — | University of Puerto Rico | Unknown | No outcome recorded |
| — | NCT06112223 | Apr → Sep 2023 | — | Tanta University | Completed | No outcome recorded |
| — | NCT07267182 | Aug 2022 → Feb 2023 | — | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT04818450 | Apr 2021 → Jun 2022 | critical illness polyneuropathy | Mahidol University | Completed | No outcome recorded |
| — | NCT06354478 | Jan 2021 → Feb 2022 | breast cancer | National Cancer Institute, Egypt | Completed | No outcome recorded |
| — | NCT04491786 | Aug 2020 → May 2021 | — | Gia Dinh People Hospital | Completed | No outcome recorded |
| — | NCT04148846 | Sep 2019 → Sep 2020 | headache disorder | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| — | NCT03826615 | Feb 2019 → Jan 2020 | cataract | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT03859102 | Dec 2018 → Oct 2019 | aneurysm or dilatation of ascending aorta, aortic valve disorder, cardiac valvular defect, coronary artery disorder +2 | James Cook University Hospital | Unknown | No outcome recorded |
| — | NCT03351439 | Apr 2018 → Sep 2021 | chronic pain syndrome | Western University, Canada | Completed | No outcome recorded |
| — | NCT04176783 | Mar 2018 → Jul 2021 | — | OrthoCarolina Research Institute, Inc. | Completed | No outcome recorded |
| — | NCT04003350 | Dec 2017 → Nov 2018 | osteoarthritis, knee | Rothman Institute Orthopaedics | Completed | Missed primary |
| — | NCT07644065 | Oct 2017 → May 2020 | anxiety, impacted teeth, multiple | Plovdiv Medical University | Completed | No outcome recorded |
| — | NCT02605187 | Nov 2015 → May 2017 | — | Stanford University | Completed | No outcome recorded |
| — | NCT02306278 | Dec 2014 → Dec 2015 | neoplasm of cerebral hemisphere | Capital Medical University | Completed | No outcome recorded |
| — | NCT02402543 | Jun 2014 → May 2017 | anal fistula, anogenital human papillomavirus infection, hemorrhoid | University of Vermont | Completed | No outcome recorded |
| — | NCT02202707 | May 2014 → Jun 2016 | — | Beth Israel Deaconess Medical Center | Withdrawn | No outcome recorded Stop: Business |
| — | NCT04345432 | Jan 2014 → Sep 2017 | postural orthostatic tachycardia syndrome | Medstar Health Research Institute | Completed | No outcome recorded |
| — | NCT02040532 | Jan 2014 → Aug 2015 | vascular disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT01623271 | May 2013 → Jun 2014 | complex regional pain syndrome type 1 | Massachusetts General Hospital | Terminated | No outcome recorded |
| — | NCT01255878 | Mar → Sep 2010 | parasomnia, sleep bruxism type | Mashhad University of Medical Sciences | Completed | No outcome recorded |
| — | NCT01265056 | Feb 2010 → Sep 2011 | — | Lucy A Wibbenmeyer | Completed | Met primary |
| — | NCT00954187 | Nov 2009 → Sep 2012 | — | Loma Linda University | Terminated | No outcome recorded |
| — | NCT00386243 | Dec 2007 → May 2012 | chronic pain syndrome | VA Office of Research and Development | Completed | Met primary |
| — | NCT00889148 | Oct 2007 → Feb 2011 | — | McMaster University | Completed | No outcome recorded |
| — | NCT01307202 | Oct 2007 → Feb 2011 | — | McMaster University | Completed | Missed primary |
| — | NCT00588159 | Jun 2007 → Jan 2010 | — | Michelle Kinney | Completed | Missed primary |
| — | NCT00218374 | Oct 2006 → Jun 2007 | opiate dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| — | NCT00577967 | Oct 2005 → Mar 2006 | uremia | Hospital Authority, Hong Kong | Unknown | No outcome recorded |
| — | NCT00187707 | Sep 2005 → Jan 2007 | — | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT00159588 | Jan 2004 → Nov 2006 | headache disorder | Norwegian University of Science and Technology | Completed | Missed primary |
| — | NCT01250561 | Feb 2002 → Oct 2007 | herpes zoster, postherpetic neuralgia | Center for Clinical Studies, Texas | Completed | No outcome recorded |
| — | NCT00022074 | Jul 2001 → Jun 2005 | anxiety disorder, breast cancer, depressive disorder | Gary Morrow | Completed | Met primary |
| — | NCT00018291 | Jan 2001 → Jan 2005 | Alzheimer disease | US Department of Veterans Affairs | Completed | No outcome recorded |
| Comparator or background therapy184 trials | ||||||
| Phase 0 | NCT04613024 Comparator | Jul → Dec 2025 | — | Stanford University | Withdrawn | No outcome recorded Stop: Business |
| Phase 0 | NCT07016451 Background | Apr 2024 → Sep 2025 | radiation cystitis | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 0 | NCT06212830 Comparator | Feb 2024 → Feb 2025 | — | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| Phase 0 | NCT05659810 Comparator | Dec 2022 → Mar 2023 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 0 | NCT05609682 Comparator | Nov 2022 → May 2024 | — | University of Oklahoma | Completed | No outcome recorded |
| Show all 184 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2024-01-30 | Zydus Lifesciences Limited | Regulatory Zydus receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 mg and 600 mg zyduslife.com ↗
Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Gabapentin Tablets (Once-Daily), 300 mg and 600 mg (USRLD: Gralise® Tablets). |
| 2023-03-27 | Lotus Pharmaceutical | Regulatory Lotus Announces MFDS Approval for GRALISE® SR, Once-Daily Tablets for Post-Herpetic Neuralgia lotuspharm.com ↗
Taipei, Taiwan, 27 March 2023 -- Lotus Pharmaceutical, a multinational pharmaceutical company (1795:TT), has announced the approval of GRALISE®, a once-daily Gabapentin extended-release tablet, by the Ministry of Food and Drug Safety of Korea (MFDS). |
| 2023-02-20 | Zydus Lifesciences Limited | Regulatory Zydus receives tentative approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 mg and 600 mg zyduslife.com ↗
Zydus Lifesciences Limited’s (including its subsidiaries/affiliates hereafter referred to as “Zydus”) subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the United States Food and Drug Administration (USFDA) for Gabapentin Tablets (Once-Daily), 300 mg and 600 mg (USRLD: Gralise® Tablets). |
| 2018-08-28 | Lupin Limited | Regulatory Lupin receives FDA approval for generic Gabapentin Tablets USP, 600 mg and 800 mg lupin.com ↗
Mumbai, Baltimore: Pharma major Lupin announced that it has received final approval for its Gabapentin Tablets USP, 600 mg and 800 mg from the United States Food and Drug Administration (FDA) to market a generic version of Pfizer Inc.’s Neurontin® Tablets, 600 mg and 800 mg. |
| 2016-09-08 | Assertio Holdings, Inc | Results Data from Depomed’s Highly-Differentiated Pain and CNS-Focused Product Portfolio Presented at PAINWeek 2016 assertiotx.com ↗
Neurological symptoms, such as tremor and visual disturbances were seen at a lower frequency for Gralise than gabapentin, with less frequent adverse events for Gralise versus gabapentin, and pregabalin, a difference which may reflect Gralise’s distinct pharmacokinetic profile. |
| 2009-01-08 | GlaxoSmithKline | Regulatory GSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome gsk.com ↗
As announced today, GSK has resubmitted to the FDA an NDA for Solzira for the treatment of moderate-to-severe primary RLS. |
| 2004-12-15 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval And Launch Of Gabapentin Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Gabapentin Tablets, 600 mg and 800 mg. |
| 2004-10-08 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Final Approval And Launch Of Gabapentin Capsules tevapharm.com ↗
Jerusalem, Israel, October 8, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Gabapentin Capsules, 100 mg, 300 mg and 400 mg. |
| 2003-10-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval for Gabapentin Tablets, 600 Mg and 800 Mg tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has granted tentative approval for the company's ANDA for Gabapentin Tablets, 600 mg and 800 mg. |
| 2003-08-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval for Gabapentin Capsules tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has issued tentative approval for the Company's ANDA for Gabapentin Capsules 100 mg, 300 mg, and 400 mg. |
| 2002-07-22 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approvable Status of Gabapentin Capsules tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted an "approvable" status for the Company's ANDA for Gabapentin Capsules 100mg, 300mg and 400mg. |
All press releases naming this drug 21 releases
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 435 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gabapentin | “Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate,...” NCT00552526 ↗423“Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin,...” NCT03636958 ↗ “Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route...” NCT04562610 ↗ “Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or...” NCT00159588 ↗ “The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.” NCT05436314 ↗ “The first group will be given gabapentin orally in a dose of 300mg Tid for 72 hours and the second group will be given oral diclofenac potassium 50mg Tid for 72 hours.” NCT06752486 ↗ “Gabapentin started on day 3 of week 1, increased up to a maximum dose of 800 mg BID by day 3 of week 2 and maintained for 2 weeks followed by 5-day taper.” NCT02543944 ↗ “The second line drug such as amitriptyline and the third line drug such as gabapentin will be adopted according to doctor's judgement if necessary.” NCT05690737 ↗ “combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids” NCT04010266 ↗ “Buprenorphine will be given along with 2 capsules of gabapentin in the morning and 2 take-home capsules of gabapentin for night.” NCT01262092 ↗ “Gabapentin syrup at 15 mg/kg and at 30 mg/kg was administered to reduce the agitation before and after oncologic procedures” NCT03681574 ↗ |
| Known as | 1-\[aminomethyl\]-cyclohexaneacetic acid | “Gabapentin (1-\[aminomethyl\]-cyclohexaneacetic acid; Neurontin, Pfizer) is an effective drug for treatment of neuropathic pain” NCT00137735 ↗ |
| Known as | Carbatin | “Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain” NCT02074267 ↗ |
| Known as | Conventin | “Group G: gabapentin group in which Patients were premedicated with oral gabapentin 1200 mg (Conventin 400mg; Evapharm) with sips of water, 2 hours before induction of anesthesia.” NCT03850093 ↗1“group II patients will receive two capsules of gabapentin (Conventin) 300 mg (total = 600 mg),” NCT07000201 ↗ |
| Known as | G-ER | “A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients...” NCT00335933 ↗2“Gabapentin Extended Release (G-ER) Tablets” NCT00636636 ↗ “Gabapentin Extended-Release (G-ER) 1200 mg” NCT00777023 ↗ |
| Known as | G-GR | “To address this notion, we characterized relationships among changes in pain intensity, sleep interference, and overall impression of improvement in PHN patients treated with...” PMID 27037091 ↗ Apr 20161“gastroretentive gabapentin (G-GR)” PMID 24149930 ↗ Jun 2014 |
| Known as | Gabapentin - Neurontin | “Gabapentin - Neurontin” NCT01020162 ↗ |
| Known as | gabapentin ER | “This study aimed to determine the efficacy and safety of gabapentin extended-release (gabapentin ER) tablets for the treatment of patients with PHN and to determine whether...” PMID 20818838 ↗ 2010 |
| Known as | Gabapentin Extended Release | “Depomed's Gabapentin Extended Release is an investigational, extended release formulation of Gabapentin that is being studied for the treatment of Hot Flashes/Hot Flushes in...” NCT01080300 ↗ |
| Known as | gabapentine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00885586 ↗ |
| Known as | gaptin | “Patients in Group B (25 participants) received gabapentin (one capsule of gaptin 100mg thrice weekly post HD session)” NCT06190132 ↗ |
| Known as | gastroretentive gabapentin | “To address this notion, we characterized relationships among changes in pain intensity, sleep interference, and overall impression of improvement in PHN patients treated with...” PMID 27037091 ↗ Apr 2016 |
| Known as | GBP | “The present study examined the impact of the N-type calcium channel blocker gabapentin (GBP) and the partial glycine agonist D-cycloserine (CYC) to attenuate the behavioral...” PMID 40272204 ↗ Apr 20252“gabapentin (GBP) plus complex B vitamins: thiamine (B1) and cyanocobalamine (B12) compared to pregabalin in patients with moderate to severe intensity PDN.” PMID 26885528 ↗ Jan 2016 “evaluated a medication combination of intravenous flumazenil (FMZ) and oral gabapentin (GBP) in alcoholics” PMID 19593171 ↗ Aug 2009 |
| Known as | Gralise | “taking Gralise pills (gastic-retentive gabapentin) for 8 weeks.” NCT01623271 ↗ |
| Known as | Gralise: Gabapentin ER | “Gralise: Gabapentin ER” NCT01764464 ↗ |
| Known as | Neurontin | “The purpose of this study is to compare the relative bioavailability of 800 mg Gabapentin Tablets by Purepac Pharmaceutical Co. with that of 400 mg (2 x 400 mg) NEURONTIN® by...” NCT00865631 ↗16“The gabapentin (Neurontin, Pfizer, Mexico) group was instructed to take one 300-mg capsule the night before surgery and 1 capsule every 8 hours on the day of surgery and for...” NCT02867176 ↗ “Baclofen(Liofen®),Diazepam,(Valium®),Clonazepam,(Klonopin®),Trihexyphenidyl(Artane®),Tetrabenazine(Xenazine®),Gabapentin(Neurontin®),Topiramate(Topamax®),Lamotrigine(Lamictal®),...” NCT04523935 ↗ “Patients will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia” NCT02384187 ↗ “Gabapentin (Neurontin) will be compared to a standard benzodiazepine, lorazepam (Ativan), for its effectiveness in treating alcohol withdrawal.” NCT00011297 ↗ “Gabapentin group (n=15): patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer).” NCT04658732 ↗ “Preliminary studies using the antiseizure medication, gabapentin (Neurontin), has demonstrated a substantial reduction in hot flashes.” NCT00112138 ↗ “Gabapentin (1-\[aminomethyl\]-cyclohexaneacetic acid; Neurontin, Pfizer) is an effective drug for treatment of neuropathic pain” NCT00137735 ↗ “Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain” NCT02074267 ↗ “Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users” NCT05319756 ↗ “Taking gabapentin (neurontin® capsule 300mg, Pfizer) medication at night as a conservative treatment” NCT05392361 ↗ |
| Known as | Neurontin (Registered Trademark) | “Gabapentin (Neurontin® (Registered Trademark))” NCT00001482 ↗2“Gabapentin (Neurontin® (Registered Trademark))” NCT07019103 ↗ “Gabapentin (Neurontin® (Registered Trademark))” NCT07777965 ↗ |
| Action | Activate | “gabapentin (Neurontin®) to activate noradrenergic activity” NCT00619983 ↗ |
| Route | Oral | “gabapentin 300 mg/day, or gabapentin 900 mg/day by mouth in three divided doses for 8 weeks.” PMID 16139656 ↗ Sep 2005 |